Clinical Trials
2 trialsNCT06630871 2024-10-10
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Fujian Medical University Union Hospital
Phase 2 Not yet recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting